Migaldendranib (MGB) is a new class of targeted nanomedicine for the treatment of diabetic macular edema (DME) and neovascular age-related ...

Recently, second-generation anti-VEGF agents, including brolucizumab, faricimab, and 8 mg aflibercept, have become available ...

A study reveals similar risks of sight-threatening diabetic retinopathy in pregnant women with type 1 diabetes compared to ...

Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session Expanded data analysis from Phase 3 Stage 1 DIAMOND program for OCS-01 ...

Left unmanaged, this diabetes-related complication can lead to vision changes. Asking your doctor the right questions can help protect your eyesight.

Diabetic macular edema is a severe complication of diabetes that affects a person's vision and can lead to blindness if left untreated.

Susvimo is under review with the EMA and once approved will be the first continuous delivery treatment for nAMD, affecting ...

Researchers say fluocinolone implants can delay proliferative diabetic retinopathy and slow progression of diabetic retinopathy in patients with diabetic macular edema.

Use of a DPP-IV inhibitor, SGLT2 inhibitor or GLP-1 receptor agonist does not increase risk for diabetic macular edema among adults with type 2 diabetes and diabetic retinopathy, according to ...

An extension of the PHOTON trial shows that aflibercept 8 mg maintains long-term visual and anatomical improvements in ...

Diabetic macular edema (DME) is a possible complication of diabetes. It happens when the tiny blood vessels in the eye get damaged from high blood sugar levels over time. In the early stages ...

Brolucizumab (Beovu) proved noninferior to aflibercept (Eylea) for visual outcomes among patients with diabetic macular edema (DME), the phase III KINGFISHER trial showed. In over 500 patients ...